BridgeBio Oncology Therapeutics Inc. (BBOT) vs Inhibikase Therapeutics, Inc. (IKT)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and Inhibikase Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.62HealthcareDelayed quote: Oct 6, 2026, 10:30 AM EDT
IKT
Inhibikase Therapeutics, Inc.
$1.98HealthcareDelayed quote: Oct 6, 2026, 10:24 AM EDT
Total return — BBOT vs IKT
growth of $100 · dividends reinvested · last 3yBBOT -64.7% (-29.3%/yr)IKT -25.4% (-9.3%/yr)IKT compounded faster over this window
BBOT IKT
BBOT vs IKT: by the numbers
- •BBOT is the larger company ($290M vs $261M market cap).
Metrics side by side
Valuation
| Metric | BBOT | IKT |
|---|---|---|
| P/B ratio | 0.90 | 1.71 |
Profitability
| Metric | BBOT | IKT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -56.36% | -39.55% |
| ROIC | -61.10% | -42.92% |
Growth (annualized)
| Metric | BBOT | IKT |
|---|---|---|
| Total return CAGR (5Y) | N/A | -29.10% |
Go deeper
Dig into the metrics
BridgeBio Oncology Therapeutics ROEInhibikase Therapeutics ROEBridgeBio Oncology Therapeutics operating marginInhibikase Therapeutics operating marginBridgeBio Oncology Therapeutics revenue growthInhibikase Therapeutics revenue growthBridgeBio Oncology Therapeutics free cash flowInhibikase Therapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.